CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that it intends to offer and sell, subject to market and other conditions, $150 million of its common stock in an underwritten public offering. As part of this offering Acceleron intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the number of shares sold. All of the shares in the offering are to be sold by Acceleron.
